DUSA PHARMACEUTICALS INC

Form 4 June 28, 2001

FORM 4	OMB APPROVAL				
Check this box if no longer subject to Section 16. Form 4					
or Form 5 obligations may continue. SEE Instruction 1(b).	Estimated average burden hours per response 0.5				
	TIES AND EXCHANGE COMMISSION CON, D.C. 20549				
STATEMENT OF CHANGE	S IN BENEFICIAL OWNERSHIP				
Section 17(a) of the Public Ut	of the Securities Exchange Act of 1934, ility Holding Company Act of 1935 or investment Company Act of 1940				
(Print or Type Responses)					
1. Name and Address of Reporting Pers	on*				
Cooper Hill Partners, LLC					
(Last) (First)	(Middle)				
230 Park Avenue					
(Street)					
New York, NY	10169				
(City) (State)	(Zip)				
2. Issuer Name and Ticker or Trading	Symbol				
DUSA Pharmaceuticals Inc. DUSA					
3. IRS or Social Security Number of R	Reporting Person (Voluntary)				
4. Statement for Month/Year					
5/01					
5. If Amendment, Date of Original (Mc					

6. Relationship of Reporting Person(s) to Issuer (Check all applicable)

	[] Director [X] 10% Owne [] Officer [] Other (s	r (giv								
- 7.	Individual o [] Form fil [X] Form fil	ed k	oy One	Reporting	Person			 e)		
ΤA	BLE INON-DE	RIVA	ATIVE	SECURITIES	ACQUIR	ED, DI:	SPOSED OF,	OR BENEF	CIALLY OWNED	
	Title of Sec (Instr. 3)	_	_	action Date (Month/ Day/	action c		or Disp	Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		
					(Instr		Amount	(A) or (D)	Price	
	mmon Stock, r value \$.01	per	share	4/4/01	P		13,100	(A)	\$11.3125	
	mmon Stock, r value \$.01	per	share	4/4/01	S		87,100	(D)	\$11.3125	
	mmon Stock, r value \$.01	per	share	5/16/01	P		41,400	(A)	\$13.52	
	mmon Stock, r value \$.01	per	share	5/29/01	Р		81,100	(A)	\$12.10	
	mmon Stock, r value \$.01	per	share	6/4/01	Р		20,600	(A)	\$11.70	
	mmon Stock, r value \$.01	per	share	6/4/01	S		25,200	(D)	\$11.70	
5.	Amount of Securities Beneficially Owned at End of Month (Instr. 3 and 4)		(D)	rship : Direct or Indirect (Instr. 4)	II Be Or	ature ondirections of the second seco	t ial ip			
	1,726,800			(I)	See	e Expl	anation of	Response	 :S	

	a separate line for irectly or indirectl	each class of securi	ties
If the form is fil 4(b)(v).	ed by more than one	reporting person, SE	E Instruction
			(Ove SEC 1474 (7-9 Page 1 of
ORM 4 (continued)			
		D, DISPOSED OF, OR B	
	Exercise (Mo Price of Da	n Date tion Code	
			(A) (I
Date Exer- cisable and Ex- piration Date (Month/Day/ Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	Derivative De Security Security (Instr. 5)	umber of erivative ecurities eneficially wned at
ate Expira- xer- tion isable Date	Amount or Title Number of Shares		nd of Month Instr. 4)

10.	Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	In Be Ow	direct neficial nership			

Explanation of Responses

As the sole general partner of CLSP, L.P.; CLSP II, L.P.; CLSP/SBS I, L.P. and CLSP/SBS II, L.P., each a private investment partnership, Cooper Hill Partners, LLC has the power to vote and dispose of the securities owned by each of these partnerships and, accordingly, may be deemed the "beneficial owner" of such securities. Jeffrey Casdin is the managing member of Cooper Hill Partners, LLC.

**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. SEE 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this form, one of which must be manually signed. If space is insufficient, SEE Instruction 6 for procedure.

/s/ Jeffrey Casdin 6/27/01

By: Jeffrey Casdin
For Cooper Hill Partners, LLC,
the general partner of CLSP,
L.P.; CLSP II, L.P.; CLSP/SBS
I, L.P. and CLSP/SBS II, L.P.,
and Individually
**Signature of Reporting Person

Page 2 of 2

Date